Mojgan Gharipour1, Masoumeh Sadeghi2, Mansour Salehi3, Mehrdad Behmanesh4, Elham Khosravi1, Minoo Dianatkhah2, Shaghayegh Haghjoo Javanmard5, Rouzbeh Razavi6, Amin Gharipour6. 1. Isfahan Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran. 2. Cardiac Rehabilitation Research Center, Isfahan Cardiovascular Research Institute, Isfahan University of Medicine Sciences, Isfahan, Iran. 3. Department of Genetics, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran. 4. Department of Genetics and Molecular Biology Medical School, Isfahan University of Medical Sciences, Isfahan, Iran. 5. Applied Physiology Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran. 6. School of Information and Communication Technology, Griffith University, Nathan Campus, Queensland, Australia.
Abstract
BACKGROUND: Selenoprotein P (SeP) is involved in transporting selenium from the liver to target tissues. Because SeP confers protection against disease by reducing chronic oxidative stress, the present study aimed to assess the level of SeP in the serum of patients with metabolic syndrome (MetS) with a history of cardiovascular disease (CVD). METHODS: A cross-sectional study was conducted in 63 and 71 subjects with and without MetS in the presence of documented CVD. All demographic, anthropometric and cardiometabolic variables (lipids, blood glucose, blood pressure) were assessed. Lifestyle-related factors and personal history and familial CVD risk factors were recorded. The expression of SELP in mRNA and protein levels in the serum was measured, and MetS was determined using ATPIII criteria. Binary logistic regression analysis demonstrated MetS and SeP to be dependent and independent variables, respectively. RESULTS: Mean of systolic and diastolic blood pressure, triglyceride, high-density lipoprotein-cholesterol, fasting blood sugar, body mass index and waist circumference were higher among subjects with MetS (p = 0.05). The mean of selenium was higher among subjects with MetS, whereas the mean of SeP was lower among subjects with MetS (p < 0.001). In the unadjusted model, the SeP had decreased odds for MetS [odds ratio (OR) = 0.995; 95% confidence interval (CI) = 0.989-1.00] (p < 0.04). Furthermore, the association between MetS and SeP levels remained marginally significant even after adjusting for potential confounders such as age, gender, family history, smoking status and nutrition. SeP and waist circumference show a significant relationship (OR =0.995; 95% CI = 0.990-1.00) (p < 0.033). CONCLUSIONS: We have demonstrated a significant decrease in circulating SeP levels according to MetS status in patients with documented cardiovascular disease.
BACKGROUND:Selenoprotein P (SeP) is involved in transporting selenium from the liver to target tissues. Because SeP confers protection against disease by reducing chronic oxidative stress, the present study aimed to assess the level of SeP in the serum of patients with metabolic syndrome (MetS) with a history of cardiovascular disease (CVD). METHODS: A cross-sectional study was conducted in 63 and 71 subjects with and without MetS in the presence of documented CVD. All demographic, anthropometric and cardiometabolic variables (lipids, blood glucose, blood pressure) were assessed. Lifestyle-related factors and personal history and familial CVD risk factors were recorded. The expression of SELP in mRNA and protein levels in the serum was measured, and MetS was determined using ATPIII criteria. Binary logistic regression analysis demonstrated MetS and SeP to be dependent and independent variables, respectively. RESULTS: Mean of systolic and diastolic blood pressure, triglyceride, high-density lipoprotein-cholesterol, fasting blood sugar, body mass index and waist circumference were higher among subjects with MetS (p = 0.05). The mean of selenium was higher among subjects with MetS, whereas the mean of SeP was lower among subjects with MetS (p < 0.001). In the unadjusted model, the SeP had decreased odds for MetS [odds ratio (OR) = 0.995; 95% confidence interval (CI) = 0.989-1.00] (p < 0.04). Furthermore, the association between MetS and SeP levels remained marginally significant even after adjusting for potential confounders such as age, gender, family history, smoking status and nutrition. SeP and waist circumference show a significant relationship (OR =0.995; 95% CI = 0.990-1.00) (p < 0.033). CONCLUSIONS: We have demonstrated a significant decrease in circulating SeP levels according to MetS status in patients with documented cardiovascular disease.
Authors: Romina di Giuseppe; Manja Koch; Ute Nöthlings; Gabi Kastenmüller; Anna Artati; Jerzy Adamski; Gunnar Jacobs; Wolfgang Lieb Journal: Endocrine Date: 2018-11-17 Impact factor: 3.633
Authors: Alexey A Tinkov; Olga P Ajsuvakova; Tommaso Filippini; Ji-Chang Zhou; Xin Gen Lei; Eugenia R Gatiatulina; Bernhard Michalke; Margarita G Skalnaya; Marco Vinceti; Michael Aschner; Anatoly V Skalny Journal: Biomolecules Date: 2020-04-24
Authors: Sophie E Ter Hark; Stéphane Jamain; Dick Schijven; Bochao D Lin; Mark K Bakker; Anne Boland-Auge; Jean-François Deleuze; Réjane Troudet; Anil K Malhotra; Sinan Gülöksüz; Christiaan H Vinkers; Bjørn H Ebdrup; René S Kahn; Marion Leboyer; Jurjen J Luykx Journal: J Psychopharmacol Date: 2020-03-04 Impact factor: 4.153